PT - JOURNAL ARTICLE AU - Louise Fritsche AU - Julia Hummel AU - Robert Wagner AU - Dorina Löffler AU - Julia Hartkopf AU - Jürgen Machann AU - Johannes Hilberath AU - Konstantinos Kantartzis AU - Peter Jakubowski AU - Jan Pauluschke-Fröhlich AU - Sara Brucker AU - Sebastian Hörber AU - Hans-Ulrich Häring AU - Michael Roden AU - Annette Schürmann AU - Michele Solimena AU - Martin Hrabe de Angelis AU - Andreas Peter AU - Andreas L. Birkenfeld AU - Hubert Preissl AU - Andreas Fritsche AU - Martin Heni TI - The German Gestational Diabetes Study (PREG): Rationale, Methodology and Design AID - 10.1101/2021.10.10.21264499 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.10.21264499 4099 - http://medrxiv.org/content/early/2021/10/11/2021.10.10.21264499.short 4100 - http://medrxiv.org/content/early/2021/10/11/2021.10.10.21264499.full AB - Introduction Since the introduction of the new International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria for gestational diabetes mellitus (GDM) in 2012, diagnosis and treatment of GDM has improved. But even well-treated GDM might still have impact on long-term health of the mother and her offspring, though, this relation has not been conclusively studied yet.Methods The multicenter PREG study is designed to metabolically and phenotypically characterize women with a 75 g five-point oral glucose tolerance test (OGTT) during and repeatedly after pregnancy. The offspring of the study participants are followed up until adulthood with developmental tests and metabolic and epigenetic phenotyping in the PREG offspring study. By in-depth phenotyping of the mother and her offspring, we aim to elucidate the relationship of maternal hyperglycemia during pregnancy and adequate treatment and its impact on the long-term health for both.Ethics and dissemination The study protocol has been reviewed and approved by the ethics committee of the University Hospital Tübingen (protocol numbers 218/2012BO2 and 617/2020BO1), the ethics committee of the Technical University Dresden (protocol number EK263072013), the ethics committee of the medical school of the Heinrich Heine University Düsseldorf (protocol number 4051) and the ethics committee of the medical school of University of Leipzig (protocol number 038-15-09032015). The results will be disseminated through conference presentations and peer-reviewed publications.Registration The PREG study and the PREG offspring study are registered with Clinical Trials (ClinicalTrials.gov Identifiers: NCT04270578, NCT04722900).Strengths and limitations of this studyThe main strength of the multicenter PREG study are the in-depth phenotyping of mothers during pregnancy and repeatedly after delivery.Data acquisition and sample handling are done according to standard operating procedures in all study sites, thus, ensuring a high quality for each data point.A PREG biobank is set up and samples are available for researchers of the German Center for Diabetes Research (DZD).Children of the study participants are repeatedly examined to cover the period of childhood and adolescence.The PREG study is not planned as a population-based cohort but is enriched for GDM cases.Data Availability Statement All requests for data and materials will be promptly reviewed by the Data Access Steering Committee to verify whether the request is subject to any intellectual property or confidentiality obligations. Individual-level data may be subject to confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement.Competing Interest StatementRW reports lecture fees from NovoNordisk and travel grants from Eli Lilly. He served on the advisory board of Akcea Therapeutics. In addition to his current work, ALB reports lecture fees from Astra Zeneca, Boehringer Ingelheim, and NovoNordisk. He served on advisory boards of Astra Zeneca, Boehringer Ingelheim and NovoNordisk. Besides his current work, AF reports lecture fees and advisory board membership from Sanofi, Novo Nordisk, Eli Lilly, and AstraZeneca. In addition to his current work, MH reports research grants from Boehringer Ingelheim and Sanofi (both to the University Hospital of Tuebingen) and lecture fees from Sanofi, Novo Nordisk, Eli Lilly and Merck Sharp Dohme. He served on an advisory board for Boehringer Ingelheim. MR serves on advisory board and/or received lecture fees from Boehringer-Ingelheim Pharma, Eli Lilly, Fishawack Group, Novo Nordisk, Sanofi US, Target NASH and Terra Firma, as well as investigator-initiated research support from Boehringer-Ingelheim, Nutricia/Danone and Sanofi-Aventis. None of the other authors report a conflict of interest directly related to the content of this work. Clinical TrialNCT04270578, NCT04722900Funding StatementThe PREG study is supported in part by a grant from the Federal Ministry of Education and Research (BMBF) (01GI0925) to the German Center for Diabetes Research (DZD). The PREG offspring study is supported by grants of the Deutsche Diabetes Stiftung (380/02/16) and the Deutsche Diabetes Gesellschaft (Helmut-Mehnert-Projektfoerderung 2020) to LF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol has been reviewed and approved by the ethics committee of the University Hospital Tuebingen (protocol numbers 218/2012BO2 and 617/2020BO1), the ethics committee of the Technical University Dresden (protocol number EK263072013), the ethics committee of the medical school of the Heinrich Heine University Duesseldorf (protocol number 4051) and the ethics committee of the medical school of University of Leipzig (protocol number 038-15-09032015).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll requests for data and materials will be promptly reviewed by the Data Access Steering Committee to verify whether the request is subject to any intellectual property or confidentiality obligations. Individual-level data may be subject to confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement. CGMcontinuous glucose monitoringfMEGfetal magnetencephalographyfMCGfetal magnetcardiographyGDMgestational diabetes mellitusMRImagnetic resonance imagingMRSmagnetic resonance spectroscopyOGTToral glucose tolerance testT2DMtype 2 diabetes mellitus